Biosimilar use in medical oncology in Ireland: a missed opportunity to mitigate financial toxicity?
- DOI
- 10.1007/s11096-026-02192-2
- Published
- 2026-07-24
- Container
- International Journal of Clinical Pharmacy
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s11096-026-02192-2,
title = {Biosimilar use in medical oncology in Ireland: a missed opportunity to mitigate financial toxicity?},
author = {Edel Burton and Kate E. Coakley and Siobhán Gaynor and Mei McDonagh and Christopher Palmer and Laura J. Sahm and Séamus O’Reilly and Unknown and Ann Doherty and Colleen Dube and Clare Fitzell and Patricia Heckmann and Siobhán Lucey and Siobhán Masterson and Anne Mooney and Éilis J. O’Reilly and Mohamad M. Saab and Emma Wallace and Bjorn Wettermark},
year = {2026},
journal = {International Journal of Clinical Pharmacy},
doi = {10.1007/s11096-026-02192-2},
url = {https://doi.org/10.1007/s11096-026-02192-2}
}RIS
TY - JOUR TI - Biosimilar use in medical oncology in Ireland: a missed opportunity to mitigate financial toxicity? AU - Edel Burton AU - Kate E. Coakley AU - Siobhán Gaynor AU - Mei McDonagh AU - Christopher Palmer AU - Laura J. Sahm AU - Séamus O’Reilly AU - Unknown AU - Ann Doherty AU - Colleen Dube AU - Clare Fitzell AU - Patricia Heckmann AU - Siobhán Lucey AU - Siobhán Masterson AU - Anne Mooney AU - Éilis J. O’Reilly AU - Mohamad M. Saab AU - Emma Wallace AU - Bjorn Wettermark PY - 2026 JO - International Journal of Clinical Pharmacy DO - 10.1007/s11096-026-02192-2 UR - https://doi.org/10.1007/s11096-026-02192-2 ER -
APA
Burton, E., Coakley, K. E., Gaynor, S., McDonagh, M., Palmer, C., Sahm, L. J., O’Reilly, S., Unknown, Doherty, A., Dube, C., Fitzell, C., Heckmann, P., Lucey, S., Masterson, S., Mooney, A., O’Reilly, É. J., Saab, M. M., Wallace, E., & Wettermark, B. (2026). Biosimilar use in medical oncology in Ireland: a missed opportunity to mitigate financial toxicity?. International Journal of Clinical Pharmacy. https://doi.org/10.1007/s11096-026-02192-2
Source records
- crossref · retrieved 2026-11-10T10:26:43.228Z